Live Breaking News & Updates on Development For Idiopathic Pulmonary Fibrosis

Stay updated with breaking news from Development for idiopathic pulmonary fibrosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pliant Therapeutics Presents Data From Its Bexotegrast Program At The American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and le ....

United States , Christopher Keenan , Gregoryp Cosgrove , Los Angeles , Jonathang Goldin , Martinl Decaris , European Medicines Agency , David Geffen School Of Medicine , Development For Idiopathic Pulmonary Fibrosis , Pliant Therapeutics Inc , University Of California , Translational Sciences At Pliant , Clinical Development At Pliant Therapeutics , Corporate Communications , American Thoracic Society , Drug Administration , International Conference , Chief Medical Officer , Dual Selective Inhibitor , Idiopathic Pulmonary Fibrosis , Primary Sclerosing Cholangitis , Vice President , Clinical Development , Pliant Therapeutics , Specific Cell Types , Fibrotic Human Lung ,

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 21, 2024 Pliant Therapeutics, Inc. , a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment. ....

United States , Jonathang Goldin , Martinl Decaris , Christopher Keenan , Los Angeles , Gregoryp Cosgrove , Drug Administration , American Thoracic Society , International Conference , Pliant Therapeutics Inc , European Medicines Agency , Corporate Communications , David Geffen School Of Medicine , Clinical Development At Pliant Therapeutics , Development For Idiopathic Pulmonary Fibrosis , University Of California , Translational Sciences At Pliant , Chief Medical Officer , Dual Selective Inhibitor , Idiopathic Pulmonary Fibrosis , Primary Sclerosing , Vice President , Clinical Development , Pliant Therapeutics , Specific Cell Types , Fibrotic Human ,